Ertugliflozin and Sitagliptin
Steglujan is a prescription brand-name medication combining ertugliflozin and sitagliptin for managing type 2 diabetes in adults. Ertugliflozin is an SGLT2 inhibitor that helps the kidneys remove glucose from the body through urine, while sitagliptin is a DPP-4 inhibitor that improves insulin production and reduces glucagon levels after meals. This combination is used when diet, exercise, and single-agent therapy do not adequately control blood sugar.
Steglujan is a two-drug combination used to lower blood sugar in adults with type 2 diabetes by helping kidneys remove glucose and improving insulin release.
Key facts at a glance
- RxNorm
- 1992827
- Generic
- Steglujan
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Steglujan is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are not adequately controlled on either ertugliflozin or sitagliptin alone, or who are already taking both medications separately.
The medication combines two mechanisms: Ertugliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and causing urinary glucose excretion; Sitagliptin inhibits the DPP-4 enzyme, which increases insulin secretion in response to meals and decreases glucagon release, helping to regulate blood glucose levels.
Steglujan is not for use in type 1 diabetes or diabetic ketoacidosis. Common side effects may include genital mycotic infections, urinary tract infections, and upper respiratory tract infections. There is a risk of dehydration, hypotension, and hypoglycemia when used with insulin or sulfonylureas. Patients should be monitored for ketoacidosis and should be advised to stop therapy if this is suspected.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 9, 2026. · Read our editorial policy